


## Vardenafil hydrochloride

## Chemical Properties

CAS No. :	224785-91-5
Formula:	C <sub>23</sub> H <sub>33</sub> ClN <sub>6</sub> O <sub>4</sub> S
Molecular Weight:	525.06
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes
Targets(IC50)	Endogenous Metabolite,PDE
In vivo	After 12 weeks of treatment, a dose-dependent (P = 0.02) improvement in erections was noted for the GAQ, with 57 and 72% of men taking 10 mg or 20 mg vardenafil, respectively, reporting improved erections, in contrast to 13% after taking placebo (P < 0.0001). For the erectile function domain, dose-dependent (P = 0.03) final scores for the 10- and 20-mg dose were 17.1 and 19.0 compared with 12.6 for placebo (P < 0.0001). Both vardenafil doses significantly enhanced the rates of successful penetration (P < 0.0001) and successful intercourse (P < 0.0001) compared with placebo. Vardenafil treatment was effective in increasing intercourse success rates at all levels of baseline ED severity, at each level of plasma HbA(1c), and for type 1 and 2 diabetes. Treatment-emergent adverse events were primarily mild to moderate headache (<or=13%), flushing (<or=10%), and rhinitis (<or=10%).

## Solubility Information

Solubility	DMSO: 50 mg/mL (95.23 mM),Sonication is recommended. H <sub>2</sub> O: 100 mg/mL (190.45 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.81 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.9045 mL	9.5227 mL	19.0454 mL
5 mM	0.3809 mL	1.9045 mL	3.8091 mL
10 mM	0.1905 mL	0.9523 mL	1.9045 mL
50 mM	0.0381 mL	0.1905 mL	0.3809 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Irwin Goldstein , Jay M Young, Jerome Fischer. Vardenafil, a New Phosphodiesterase Type 5 Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes: A Multicenter Double-Blind Placebo-Controlled Fixed-Dose Study. *Diabetes Care*. 2003 Mar;26(3):777-83.

Saenz de Tejada, I., et al., The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. *Int J Impot Res*, 2001. 13(5): p. 282-90.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481